GlassScriptPhysician profile
Suzanne P Paige
NPI 1538649157
$12,230.21
in general payments reported to CMS, 2019-2025
67 companies · $2,631 in 2025
The $2,631 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,316 · 2022: $2,606 · 2023: $2,540 · 2024: $3,137 · 2025: $2,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,238 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,238.37 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $908.65 | 2021-2025 | Imfinzi, Enhertu, Calquence |
| Incyte Corporation | $793.75 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Pfizer INC. | $774.81 | 2021-2025 | |
| Janssen Biotech, INC. | $726.28 | 2021-2025 | Darzalex, Rybrevant, Erleada |
| Novartis Pharmaceuticals Corporation | $702.91 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $623.24 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $548.94 | 2021-2023 | Adcetris, Tukysa, Tivdak |
| Eisai INC. | $529.14 | 2021-2025 | |
| Genzyme Corporation | $511.52 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $401.20 | 2022-2025 | Opdivo, Krazati, Opdualag |
| Astellas Pharma US INC | $369.37 | 2021-2025 | Vyloy, Xtandi, Padcev |
| Amgen INC. | $333.00 | 2021-2023 | Lumakras, Blincyto, Kyprolis |
| Daiichi Sankyo INC. | $319.64 | 2021-2025 | Enhertu, Vanflyta |
| Regeneron Healthcare Solutions, INC. | $305.51 | 2021-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $298.29 | 2021-2024 | Fruzaqla, Alunbrig, Iclusig |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $234.85 | 2022-2025 | Ultomiris |
| Celgene Corporation | $212.30 | 2022-2025 | Reblozyl |
| Jazz Pharmaceuticals INC. | $197.00 | 2021-2025 | |
| Array Biopharma INC | $194.09 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Gilead Sciences, INC. | $167.23 | 2023-2025 | Trodelvy |
| Genentech USA, INC. | $158.15 | 2021-2025 | Tecentriq, Polivy, Itovebi |
| Bayer Healthcare Pharmaceuticals INC. | $154.41 | 2022-2025 | |
| Taiho Oncology, INC. | $151.27 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $143.49 | 2023-2024 | Monoferric, Cosela |
| Sobi, INC | $139.50 | 2022-2025 | |
| Servier Pharmaceuticals LLC | $136.16 | 2021-2025 | |
| Abbvie INC. | $132.69 | 2023-2025 | |
| Lilly USA, LLC | $129.83 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| Emd Serono, INC. | $102.03 | 2023-2025 | Bavencio |
| Aveo Pharmaceuticals, INC. | $98.28 | 2022-2025 | Fotivda |
| Geron Corporation | $98.23 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $96.18 | 2023-2025 | Orserdu |
| Puma Biotechnology, INC. | $88.46 | 2021-2025 | |
| Agios Pharmaceuticals, INC. | $84.53 | 2023-2025 | Pyrukynd |
| Beigene USA, INC. | $83.61 | 2023-2025 | Brukinsa |
| Octapharma USA, INC. | $82.73 | 2021 | |
| G1 Therapeutics, INC. | $81.63 | 2022-2023 | Cosela |
| Genmab U.S., INC. | $79.93 | 2023-2025 | Epkinly |
| Mirati Therapeutics, INC. | $74.50 | 2023-2024 | Krazati |
| Beone Medicines USA, INC. | $72.36 | 2025 | Brukinsa |
| Pharmaessentia USA Corporation | $72.12 | 2023-2025 | Besremi |
| Blueprint Medicines Corporation | $64.34 | 2022-2025 | Ayvakit |
| Myriad Genetic Laboratories, INC. | $62.24 | 2023-2024 | Precisetumor, Myrisk |
| Pharmacyclics LLC, An Abbvie Company | $59.53 | 2021-2023 | Epkinly, Imbruvica |
| Iovance Biotherapeutics, INC. | $53.87 | 2025 | Amtagvi |
| Tolmar, INC. | $51.58 | 2024-2025 | Rubraca, Eligard |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.65 | 2021-2022 | |
| Cti Biopharma Corp. | $45.83 | 2023 | Vonjo |
| Recordati_rare_diseases_inc. | $39.19 | 2023-2025 | Enjaymo, Sylvant |
| Sun Pharmaceutical Industries INC. | $38.59 | 2025 | |
| Tersera Therapeutics LLC | $30.69 | 2023 | Quzyttir |
| Pharmaand Gmbh | $28.56 | 2025 | Rubraca |
| Kyowa Kirin, INC. | $28.03 | 2021-2024 | Poteligeo |
| Glaxosmithkline, LLC. | $27.01 | 2022 | |
| Adc Therapeutics America, INC. | $24.86 | 2024 | |
| Amag Pharmaceuticals, INC. | $22.46 | 2021 | |
| Morphosys, US INC. | $21.84 | 2023 | Monjuvi |
| Apellis Pharmaceuticals, INC. | $20.87 | 2024 | Empaveli |
| Acrotech Biopharma INC. | $20.11 | 2024 | Beleodaq |
| Rigel Pharmaceuticals, INC. | $19.93 | 2024 | Rezlidhia, Tavalisse |
| Menarini Silicon Biosystems, INC. | $18.48 | 2025 | |
| Syndax Pharmaceuticals, INC. | $17.29 | 2025 | |
| Epizyme, INC. | $16.43 | 2022 | |
| Exelixis INC. | $16.41 | 2024 | Cabometyx |
| Legend Biotech USA INC. | $15.08 | 2025 | Carvykti |
| Ipsen Biopharmaceuticals, INC | $14.47 | 2025 | Somatuline Depot, Onivyde |
| Global Blood Therapeutics, INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Paige listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.